Key takeaway: HealthCare Global Enterprises Limited (HCG) reported its unaudited financial results for the quarter ended June 30, 2026, during the investor presentation dated August 6, 2026. The company achieved a revenue of INR 6,951 million, reflecting a 13% year-on-year growth, driven by an 11% increase in patient volumes. Adjusted EBITDA rose by 20% to INR 1,339 million, with margins improving to 19.4%. The presentation highlighted the operationalization of the North Bengaluru hospital, which added 120+ beds and contributed INR 67 million in revenue during its first quarter. HCG also completed a rights issue to strengthen its balance sheet and enhance financial flexibility. The company emphasized its strategic focus on core oncology, operational excellence, and capacity expansion, with plans to add 1,000 beds by FY30, primarily through brownfield expansion. The management underscored the importance of enhancing patient experience and optimizing costs.

Key takeaway: HealthCare Global Enterprises Limited (HCG) held its earnings conference call on May 20, 2026, to discuss its financial results for Q4 and FY26. Management reported that FY26 was a significant year, marked by broad-based profitable growth, with revenues reaching INR 2,545 crore, a 15% increase year-on-year. Key milestones included the opening of a new oncology facility in North Bangalore and the successful completion of a rights issue raising INR 425 crore. Management emphasized a strategic focus on oncology, highlighted by the decision to divest its fertility business, Milann, to Inviga Healthcare Fund for INR 37.6 crore. The company also reported an adjusted EBITDA of INR 471.1 crore for FY26, reflecting improved margins and operational efficiency. Management noted ongoing efforts to enhance patient acquisition through digital channels and plans for further capacity expansion across various regions. The call concluded with management expressing confidence in future growth driven by strategic initiatives and market demand.

Key takeaway: HealthCare Global Enterprises Limited (HCG) reported its annual financial results for the year ended March 31, 2026, during the investor presentation dated May 19, 2026. The company achieved a revenue of INR 25,454 million, reflecting a 15% year-over-year growth, supported by sustained volume growth and improved average revenue per patient (ARPP). The presentation highlighted broad-based growth across various regions, with the West being the key growth driver. Adjusted EBITDA for FY26 was reported at INR 4,711 million, up 19% year-over-year, with an adjusted EBITDA margin of 18.5%. HCG also announced the divestment of its non-core fertility business, Milann, to enhance focus on its oncology services. The company emphasized its strategic priorities, including expanding its network and improving operational efficiency. Additionally, HCG's North Bangalore facility commenced operations, introducing advanced MR-LINAC technology.

Key takeaway: HealthCare Global Enterprises Limited (HCG) held its earnings conference call on February 9, 2026, to discuss its unaudited financial results for the quarter and nine months ended December 31, 2025. Management reported a revenue of INR 633 crore for Q3 FY26, reflecting a year-on-year growth of 13.4%. The company emphasized its focus on strengthening its oncology platform and improving clinical outcomes. Digital revenue grew by 26% year-on-year, with outpatient and inpatient volumes increasing by 26% and 37%, respectively. Adjusted EBITDA for Q3 was INR 111 crore, with margins expanding to 17.5%. Management highlighted ongoing growth potential in existing centers and plans for brownfield and greenfield expansions. The company aims for a revenue growth of 15%+, driven by volume and average revenue per patient (ARPP) increases. Management also discussed the impact of external factors, including a strike in Andhra Pradesh, on performance, but expressed confidence in future growth and operational momentum.

Key takeaway: HealthCare Global Enterprises Limited (HCG) submitted an updated Investor Presentation on its unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation reported a revenue of INR 6,331 million for Q3 FY26, reflecting a growth of approximately 13% year-over-year. The growth was attributed to an 8% increase in volumes and a 5% rise in average revenue per patient (ARPP). The West cluster showed the highest revenue growth at around 17% YoY. Adjusted EBITDA for Q3 FY26 was INR 1,108 million, marking a 20% increase YoY, with overall adjusted EBITDA margins improving to 17.5%. The presentation also highlighted the completion of senior leadership roles and the ongoing development of a new hospital in North Bangalore, which is set to offer advanced MR-LINAC technology. HCG's international business in Africa grew by approximately 42% YoY, contributing to its overall performance.